Fig. 2

Silencing of TRIB3 inhibits in vivo tumor growth. An in vivo experiment was conducted using the inducible pLKO-3xLacO system in the RH30 cell line. a Tumor growth (left panel) and survival (right panel) of control plasmid-derived tumors showed no significant differences after induction. b TRIB3 protein levels in tumors were analyzed by WB (left panel) and quantified (right panel). c Induction of sh84 in tumor cells resulted in delayed tumor growth (left panel) and improved survival (right panel). d WB analysis revealed decreased TRIB3 protein levels after IPTG induction (left panel), with a significant reduction of approximately 50% observed in induced tumors at the end of the experiment (right panel). e Mice from the sh84 group, sacrificed at 7, 11, and 14 days, showed a significant decrease in both tumor volume (upper panel) and tumor weight (lower panel). f Analysis of tumor samples by WB showed a decrease in MYCN and myogenin levels, along with decreases in total Akt levels and in the phosphorylation status of its substrate PRAS40. In (b, d) each lane represents a sample from an individual mouse. FP: fusion protein. P: phosphorylated